Reversibility of inhibition of human type II nitric oxide synthase.
Nicholls
D J
DJ
Biochemistry Department, Astra Charnwood, Loughborough, U.K.
Kirk
A
A
Wallace
A V
AV
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D002460:Cell Line; D003110:Colonic Neoplasms; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis; D007550:Isothiuronium / Q000031:analogs & derivatives / Q000494:pharmacology; D007700:Kinetics; D008264:Macrophages; D051379:Mice; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D019335:Nitroarginine; D009861:Onium Compounds / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D019323:omega-N-Methylarginine
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D009861:Onium Compounds; D019335:Nitroarginine; D007550:Isothiuronium; C007687:etiron; D019323:omega-N-Methylarginine; C045716:adenosine 2',5'-diphosphate; D000244:Adenosine Diphosphate; C007517:diphenyleneiodonium; D001120:Arginine; D019001:Nitric Oxide Synthase